Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage, vertically integrated, leading CellTech bio-developer.
Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics.
And right now, the company has several potential catalysts that could spark a near term vertical chart move. They include:
#1. - End Of Year Business Update, Focus On 2022
#2. - Chairman Provides De-bt Con-version
#3. - Company Advances AI-Enhanced Protein Design Tech
#4. - Filing US & International Patent Application For Breakthrough Tech
So let's break those down quickly...
#1. AVCO Potential Catalyst - End Of Year Business Update, Focus On 2022
Avalon GloboCare Provides Year-End Business Update of Selective Scientific and Clinical Programs
FREEHOLD, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today provided a year-end business update.
[...]
Read the full article here.
-----
#2. AVCO Potential Catalyst - Chairman Provides Debt Conversion
Avalon GloboCare’s Chairman Converts Debt into Common St-ock at 45% Premium to Market
FREEHOLD, N.J., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced the Company’s Chairman, Daniel Lu, has converted $3.0Mn of debt owed to him under the Line of Credit into 2.4 million shares of the Company’s common st-ock at $1.25 per share. The conversion price represents a 45% premium to yesterday’s closing price.
[...]
Read the full article here.
-----
#3. AVCO Potential Catalyst - Company Advances AI-Enhanced Protein Design Tech
Avalon GloboCare Advances AI-Enhanced Protein Design Technology for Cellular Therapy Development
FREEHOLD, N.J., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced further advancement of the Company’s sponsored research and licensing agreement with the Massachusetts Institute of Technology (MIT). Avalon and MIT have combined their artificial intelligence (AI)-enhanced protein design “QTY Code” technology with Google’s AlphaFold2, a DeepMind AI program developed to predict 3-dimensional (3D) protein structures of previously difficult to work with dr-ug targets. This new system is designed to accelerate and advance Avalon’s capabilities in developing novel targets for immuno-oncology and cellular medicine.
[...]
“This new study with our collaborator, Dr. Shuguang Zhang from MIT, has validated the innovative application of the QTY code technology to transform important cellular therapy targets that have been previously difficult to work with in the laboratory,” said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon. “This new approach is advancing our capabilities in designing novel immuno-oncology and cellular medicine therapies and we are excited to continue to work with Dr. Zhang to advance these dr-ug development technologies,” added Dr. Jin.
[...]
Read the full article here.
-----
#4. AVCO Potential Catalyst - Filing US & International Patent Application For Breakthrough Tech
Avalon GloboCare Jointly Files US and International Patent Application for Breakthrough S-Layer Coated Emulsome Technology (SLET) for Next-Generation Dr-ug Delivery and Cellular Immunotherapy
FREEHOLD, N.J., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today announced it has successfully co-developed a novel platform of S-layer coated emulsome technology (SLET) for next-generation dr-ug delivery and cellular immunotherapy, together with Professor Uwe Sleytr and the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria.
[...]
“We are very excited to announce this novel SLET platform, which we believe will help accelerate the development of our mRNA-based Flash-CAR™ program. The targeted delivery of mRNA to immune effector cells by SLET could open the door to a whole new generation of cancer immunotherapy. In addition, we see a number of other therapeutic and diagnostic applications for this broad and potentially transformative technology platform. Moreover, we believe these latest patent filings will provide us robust international IP protection for this technology and its many potential applications,” said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon.
Read the full article now.
-----
AVCO Recap - 4 Potential Driver Indicators For This Nasdaq Biotech Idea
#1. - End Of Year Business Update, Focus On 2022
#2. - Chairman Provides De-bt Con-version
#3. - Company Advances AI-Enhanced Protein Design Tech
#4. - Filing US & International Patent Application For Breakthrough Tech
-----
Coverage is officially initiated on AVCO. When you have time later, do this:
